These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 29204959)

  • 1. Insights into the bisphosphonate holiday: a preliminary FTIRI study.
    Boskey AL; Spevak L; Ma Y; Wang H; Bauer DC; Black DM; Schwartz AV
    Osteoporos Int; 2018 Mar; 29(3):699-705. PubMed ID: 29204959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.
    Hofstetter B; Gamsjaeger S; Varga F; Dobnig H; Stepan JJ; Petto H; Pavo I; Klaushofer K; Paschalis EP
    Osteoporos Int; 2014 Dec; 25(12):2709-19. PubMed ID: 25037600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
    Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR;
    JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties.
    Hassler N; Gamsjaeger S; Hofstetter B; Brozek W; Klaushofer K; Paschalis EP
    Osteoporos Int; 2015 Jan; 26(1):339-52. PubMed ID: 25315260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Gamsjaeger S; Buchinger B; Zoehrer R; Phipps R; Klaushofer K; Paschalis EP
    Bone; 2011 Dec; 49(6):1160-5. PubMed ID: 21893225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.
    Mignot MA; Taisne N; Legroux I; Cortet B; Paccou J
    Osteoporos Int; 2017 Dec; 28(12):3431-3438. PubMed ID: 28875236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
    Boskey AL; Marino J; Spevak L; Pleshko N; Doty S; Carter EM; Raggio CL
    Clin Orthop Relat Res; 2015 Aug; 473(8):2587-98. PubMed ID: 25903941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
    Durchschlag E; Paschalis EP; Zoehrer R; Roschger P; Fratzl P; Recker R; Phipps R; Klaushofer K
    J Bone Miner Res; 2006 Oct; 21(10):1581-90. PubMed ID: 16995813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.
    Nayak S; Greenspan SL
    Osteoporos Int; 2019 Apr; 30(4):705-720. PubMed ID: 30623214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women.
    Boskey AL; Spevak L; Weinstein RS
    Osteoporos Int; 2009 May; 20(5):793-800. PubMed ID: 18769963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX).
    Roschger P; Lombardi A; Misof BM; Maier G; Fratzl-Zelman N; Fratzl P; Klaushofer K
    J Bone Miner Res; 2010 Jan; 25(1):48-55. PubMed ID: 19580465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial.
    Paschalis EP; Glass EV; Donley DW; Eriksen EF
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4644-9. PubMed ID: 15914535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence of altered matrix composition in iliac crest biopsies from patients with idiopathic juvenile osteoporosis.
    Garcia I; Chiodo V; Ma Y; Boskey A
    Connect Tissue Res; 2016; 57(1):28-37. PubMed ID: 26539896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Misof BM; Paschalis EP; Blouin S; Fratzl-Zelman N; Klaushofer K; Roschger P
    J Bone Miner Res; 2010 Nov; 25(11):2297-303. PubMed ID: 20683883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate.
    Bala Y; Farlay D; Chapurlat RD; Boivin G
    Eur J Endocrinol; 2011 Oct; 165(4):647-55. PubMed ID: 21821631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examining the Relationships Between Bone Tissue Composition, Compositional Heterogeneity, and Fragility Fracture: A Matched Case-Controlled FTIRI Study.
    Boskey AL; Donnelly E; Boskey E; Spevak L; Ma Y; Zhang W; Lappe J; Recker RR
    J Bone Miner Res; 2016 May; 31(5):1070-81. PubMed ID: 26636271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients' reasons for adhering to long-term alendronate therapy.
    Pepe J; Cipriani C; Cecchetti V; Ferrara C; Della Grotta G; Danese V; Colangelo L; Minisola S
    Osteoporos Int; 2019 Aug; 30(8):1627-1634. PubMed ID: 31089764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring.
    McNabb B; Vittinghoff E; Eastell R; Schwartz AV; Bauer DC; Ensrud K; Barrett-Connor E; Black DM
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4094-100. PubMed ID: 25127011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
    J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.